| Objectives By observing the relevant curative effect indexes of the experience prescription Hezhong Qingwei Yin in the treatment of patients with chronic non-atrophic gastritis with spleen and stomach damp-heat syndrome,to evaluate its clinical efficacy and safety.Methods Sixty patients with chronic non-atrophic gastritis with spleen and stomach damp-heat syndrome were divided into a treatment group and a control group with 30 cases each according to a random number table.The treatment group was given the experience prescription Hezhong Qingwei Yin orally,and the control group was given rabeprazole sodium enteric-coated capsules with mosapride citrate dispersible tablets.The treatment course of the two groups was 4 weeks,during which other related treatment measures were stopped.After the treatment,the gastric mucosal manifestations,TCM syndrome scores,clinical outcome measurement scale scores(Patient Reported Outcome,PRO)and liver and kidney function indexes of patients with chronic gastrointestinal diseases were observed,and SPSS 22.0 was used to compare the above The data is comprehensively analyzed.If the measurement data conforms to the normal distribution,the t test is used.If the measurement data does not conform to the normal distribution,the rank sum test is used.The rank data uses the rank sum test.The enumeration data sample uses the chi-square test.All of the above are statistically significant with P < 0.05.Based on the statistical results,the clinical efficacy and safety of the experience prescription Hezhong Qingwei Yin in the treatment of chronic non-atrophic gastritis with spleen and stomach damp-heat syndrome were objectively evaluated.Results 1 Comparison of the efficacy of gastric mucosa between the two groups after treatment: the effective rate of the treatment group was 90%,and the effective rate of the control group was 80%.The difference was statistically significant(P < 0.05).The efficacy of Hezhong Qingwei Yin was better than that of western medicine(P < 0.05);2Comparison of the efficacy of TCM syndromes between the two groups after treatment:the total effective rate of the treatment group was 90%,and the total effective rate of the control group was 76.7%,the difference was statistically significant(P < 0.05),the curative effect of Hezhong Qingwei Yin in TCM syndromes is significantly better than that of western medicine(P < 0.05);after treatment,the total score of TCM syndromes in the two groups has obvious curative effect(P < 0.05),but the effect of Hezhong Qingwei Yin is more prominent(P < 0.05);single TCM in the treatment group Syndrome scores all have obvious curative effect(P < 0.05).In the control group,except for mental drowsiness,all syndromes have obvious curative effect(P < 0.05).They are drowsy,sticky and bitter in the mouth,sticky or loose stools.In terms of stagnation,poor appetite,nausea and vomiting,abdominal burning,and mental drowsiness,Hezhong Qingwei Yin is more effective than western medicine(P < 0.05).In terms of abdominal distension or pain,the two groups have the same effect;3 After two treatments comparison of PRO scale scores between the two groups: the difference was statistically significant(P < 0.05),and the efficacy of Hezhong Qingwei Yin was significantly better than that of western medicine(P< 0.05);4 Comparison of liver and kidney function between the two groups before and after treatment: the difference was not statistically significant(P > 0.05),and there were no obvious abnormalities in blood,urine,stool routine,and electrocardiogram.No serious adverse reactions and adverse events occurred.Conclusions Hezhong Qingwei Yin can effectively improve gastric mucosal inflammation,TCM syndromes and quality of life in patients with chronic non-atrophic gastritis with spleen and stomach damp-heat syndrome.It is significantly better than rabeprazole sodium enteric-coated capsules and mosapride citrate dispersible tablets,and has higher safety.Figure0;Table21;Reference 145... |
PDF Full Text Request